Terms: = Lymphoma AND RB1, OSRC, ENSG00000139687, 5925, RB, P06400
509 results:
1. Combination of minimal residual disease on day 15 and copy number alterations results in BCR-ABL1-negative pediatric B-ALL: A powerful tool for prediction of induction failure.
Baghdadi H; Soleimani M; Zavvar M; Bahoush G; Poopak B
Cancer Genet; 2024 Apr; 282-283():27-34. PubMed ID: 38183785
[TBL] [Abstract] [Full Text] [Related]
2. DNA Copy Number Alterations and Copy Neutral Loss of Heterozygosity in Adult Ph-Negative Acute B-Lymphoblastic Leukemia: Focus on the Genes Involved.
Risinskaya N; Gladysheva M; Abdulpatakhov A; Chabaeva Y; Surimova V; Aleshina O; Yushkova A; Dubova O; Kapranov N; Galtseva I; Kulikov S; Obukhova T; Sudarikov A; Parovichnikova E
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139431
[TBL] [Abstract] [Full Text] [Related]
3. Adding a Gene Expression Profile Test to Aid Differential Diagnosis and Treatment in Aggressive Large B-Cell lymphoma: An Early Exploratory Economic Evaluation.
Bouttell J; Fraser H; Goodlad JR; Hopkins D; McKay P; Oien KA; Seligmann B; von Delft S; Hawkins N
Appl Health Econ Health Policy; 2024 Mar; 22(2):243-254. PubMed ID: 38017318
[TBL] [Abstract] [Full Text] [Related]
4. Anaplastic Large Cell Transformation of Mycosis Fungoides: Case Report and Review of the Literature.
Flerova E; Alpdogan O; Bhatti S; Nikbakht N; Wang ZX; Gong JZ
Am J Dermatopathol; 2023 Sep; 45(9):e74-e82. PubMed ID: 37625813
[TBL] [Abstract] [Full Text] [Related]
5. Antitumor Effect of Galectin-9 on Cell Proliferation and Tumor Growth of Human Duodenal Adenocarcinoma Cells.
Kono T; Fujihara S; Oura K; Iwama H; Fujita K; Fujita N; Takuma K; Ono M; Namima D; Yamana H; Chiyo T; Kobayashi K; Kamada H; Kobara H; Ono M; Niki T; Hirashima M; Masaki T
Anticancer Res; 2023 Aug; 43(8):3769-3777. PubMed ID: 37500141
[TBL] [Abstract] [Full Text] [Related]
6. PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma.
Sloan SL; Brown F; Long M; Weigel C; Koirala S; Chung JH; Pray B; Villagomez L; Hinterschied C; Sircar A; Helmig-Mason J; Prouty A; Brooks E; Youssef Y; Hanel W; Parekh S; Chan WK; Chen Z; Lapalombella R; Sehgal L; Vaddi K; Scherle P; Chen-Kiang S; Di Liberto M; Elemento O; Meydan C; Foox J; Butler D; Mason CE; Baiocchi RA; Alinari L
Blood; 2023 Sep; 142(10):887-902. PubMed ID: 37267517
[TBL] [Abstract] [Full Text] [Related]
7. Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi.
Nizzoli ME; Manni M; Ghiggi C; Pulsoni A; Musuraca G; Merli M; Califano C; Bari A; Massaia M; Conconi A; Musto P; Mannina D; Perrone T; Re F; Galimberti S; Gini G; Capponi M; Vitolo U; Usai SV; Stefani PM; Ballerini F; Liberati AM; Pennese E; Pastore D; Skrypets T; Catellani H; Marcheselli L; Federico M; Luminari S
Hematol Oncol; 2023 Oct; 41(4):655-662. PubMed ID: 37246287
[TBL] [Abstract] [Full Text] [Related]
8. Identification and validation of a cellular senescence-related lncRNA signature for prognostic prediction in patients with multiple myeloma.
Zeng T; Jiang S; Wang Y; Sun G; Cao J; Hu D; Wang G; Liang X; Ding J; Du J
Cell Cycle; 2023 Jun; 22(12):1434-1449. PubMed ID: 37227248
[TBL] [Abstract] [Full Text] [Related]
9. Plasma cell myeloma with RAS/BRAF mutations is frequently associated with a complex karyotype, advanced stage disease, and poorer prognosis.
Li N; Lin P; Zuo Z; You MJ; Shuai W; Orlowski R; Manasanch EE; Li S; Xu J; Garces S; Jelloul FZ; Tang Z; Wang W; Medeiros LJ; Yin CC
Cancer Med; 2023 Jul; 12(13):14293-14304. PubMed ID: 37212518
[TBL] [Abstract] [Full Text] [Related]
10. TP53 and rb1 alterations characterize poor prognostic subgroups in pediatric acute myeloid leukemia.
Hara Y; Shiba N; Yoshida K; Yamato G; Kaburagi T; Shiraishi Y; Ohki K; Shiozawa Y; Kawamura M; Kawasaki H; Sotomatsu M; Takizawa T; Matsuo H; Shimada A; Kiyokawa N; Tomizawa D; Taga T; Ito E; Horibe K; Miyano S; Adachi S; Taki T; Ogawa S; Hayashi Y
Genes Chromosomes Cancer; 2023 Jul; 62(7):412-422. PubMed ID: 37102302
[TBL] [Abstract] [Full Text] [Related]
11. A phase I study of the combination of palbociclib and dexamethasone for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia.
Wilde L; Porazzi P; Trotta R; De Dominici M; Palmisiano N; Keiffer G; Rancani K; Yingling K; Calabretta B; Kasner M
Leuk Res; 2023 Jun; 129():107075. PubMed ID: 37079999
[TBL] [Abstract] [Full Text] [Related]
12. Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up.
Davies AJ; Barrans S; Stanton L; Caddy J; Wilding S; Saunders G; Mamot C; Novak U; McMillan A; Fields P; Collins GP; Stephens R; Cucco F; Sha C; van Hoppe M; Tooze R; Davies JR; Griffiths G; Schuh A; Burton C; Westhead DR; Du MQ; Johnson PWM
J Clin Oncol; 2023 May; 41(15):2718-2723. PubMed ID: 36972491
[No Abstract] [Full Text] [Related]
13. Cytotoxic Effects of Darinaparsin, a Novel Organic Arsenical, against Human Leukemia Cells.
Yuan B; Kikuchi H; Li J; Kawabata A; Yao K; Takagi N; Okazaki M
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768603
[TBL] [Abstract] [Full Text] [Related]
14. [A Case of Malignant Rectal B Cell lymphoma That Was Difficult to Differentiate from Rectal Neuroendocrine Tumor].
Murao S; Danno K; Nakamichi I; Takeda T; Fujino S; Takada N; Yamamoto K; Higashiguchi M; Noguchi K; Toyoda Y; Nakane S; Yamamoto H; Hirao T; Oka Y
Gan To Kagaku Ryoho; 2022 Dec; 49(13):1793-1795. PubMed ID: 36733001
[TBL] [Abstract] [Full Text] [Related]
15. Retinoblastoma Protein Is Required for Epstein-Barr Virus Replication in Differentiated Epithelia.
Myers JE; Schaal DL; Nkadi EH; Ward BJH; Bienkowska-Haba M; Sapp M; Bodily JM; Scott RS
J Virol; 2023 Feb; 97(2):e0103222. PubMed ID: 36719239
[TBL] [Abstract] [Full Text] [Related]
16. Evaluation of 4 prognostic indices in follicular lymphoma treated in first line with immunochemotherapy.
Rodríguez-Sevilla JJ; Fernández-Rodríguez C; Bento L; Diez-Feijóo R; Pinzón S; Gibert J; Fernández-Ibarrondo L; Lafuente M; Ferrer A; Sánchez-González B; Gimeno E; Sainz J; Ramos R; García JF; Colomo L; Bellosillo B; Gutiérrez A; Salar A
Blood Adv; 2023 Apr; 7(8):1606-1614. PubMed ID: 36260737
[TBL] [Abstract] [Full Text] [Related]
17. Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report.
Wiedemann C; Kazdal D; Cvetkovic J; Kunz J; Fisch D; Kirchner M; Kriegsmann M; Sültmann H; Heussel CP; Bischoff H; Thomas M; Stenzinger A; Christopoulos P
Cold Spring Harb Mol Case Stud; 2022 Oct; 8(6):. PubMed ID: 36207130
[TBL] [Abstract] [Full Text] [Related]
18. Molecular markers related to patient outcome in patients with IDH-mutant astrocytomas grade 2 to 4: A systematic review.
Tesileanu CMS; Vallentgoed WR; French PJ; van den Bent MJ
Eur J Cancer; 2022 Nov; 175():214-223. PubMed ID: 36152406
[TBL] [Abstract] [Full Text] [Related]
19. Targeted Treatment and Immunotherapy in High-risk and Relapsed/ Refractory Pediatric Acute Lymphoblastic Leukemia.
Graiqevci-Uka V; Behluli E; Spahiu L; Liehr T; Temaj G
Curr Pediatr Rev; 2023; 19(2):150-156. PubMed ID: 36056858
[TBL] [Abstract] [Full Text] [Related]
20. Genotyping of cerebrospinal fluid in lung cancer patients with leptomeningeal metastasis.
Nie N; Zhou H; Zhang K; Liu L; Luo N; Wang R; Li X; Zhu M; Hu C; Wang Y; Liu Z; Li L; He Y
Thorac Cancer; 2022 Sep; 13(18):2574-2583. PubMed ID: 35896160
[TBL] [Abstract] [Full Text] [Related]
[Next]
